Treatment of neuromyelitis optica

Current Opinion in Ophthalmology

Volumn 26, Issue 6, 2015, Pages 476-483

  Vodopivec, Ivana ^a   Matiello, Marcelo ^a,b   Prasad, Sashank ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiaquaporin 4 antibodies; Myelitis; Neuromyelitis optica; Optic neuritis; Treatment

Indexed keywords

AQUAPORIN; AQUAPORUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ECULIZUMAB; GLUCOCORTICOID; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLATE MOFETIL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NMO IMMUNOGLOBULIN G; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

CLINICAL FEATURE; DISEASE EXACERBATION; DRUG MECHANISM; EARLY DIAGNOSIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MYELOOPTIC NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SERODIAGNOSIS; TREATMENT DURATION; TREATMENT INDICATION; ANALOGS AND DERIVATIVES; ANIMAL; TREATMENT OUTCOME;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; NEUROMYELITIS OPTICA; RITUXIMAB; TREATMENT OUTCOME;

EID: 84944216304     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000202     Document Type: Review

References (92)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
2. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477.
3. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 2015;21:845-853. This review analyses demographic and clinical features of NMO in different geographic regions and among diverse populations.
4. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 2012;69:1176-1180.
5. Goodin DS. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol 2014;122:231-266. This thorough review summarizes current knowledge about the natural history and pathogenesis of MS established by studying the epidemiology of the disease.
6. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica (Devic's syndrome). Handb Clin Neurol 2014;122:581-599. This review gives a broad overview of NMO, including history and nomenclature, diagnostic criteria, clinical features, pathogenesis and treatment.
7. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68:603-605.
8. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology2013;81:1197-1204.
9. Collongues N, Cabre P, Marignier R, et al. A benign form of neuromyelitis optica: does it exist? Arch Neurol 2011;68:918-924.
10. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834-1849.
11. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60:848-853.
12. Cabre P, González-Quevedo A, Bonnan M, et al. Relapsing neuromyelitis optica: long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry 2009;80:1162-1164.
13. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65:1479-1482.
14. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
15. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
16. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
17. Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012;32:216-220.
18. Bennett J, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler 2015;21:678-688. This review summarizes the utility of OCT in differentiating NMO from MS in clinical practice and investigational studies.
19. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007;114:810-815.
20. Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84:1165-1173. This review highlights the brain MRI findings in NMOSD.
21. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organspecific autoimmunity. Arch Neurol 2008;65:78-83.
22. Jarius S, Jacobi C, de Seze J, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 2011;17:1067-1073.
23. Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 2014;47:154-161. This is a comprehensive review of the current literature on autoimmune disorders coexisting with NMO. It also examines the association of cancer and NMO.
24. Matiello M, Schaefer-Klein J, Sun D, Weinshenker BG. Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 2013;70:1118-1125.
25. Saadoun S, Papadopoulos MC. Role of membrane complement regulators in neuromyelitis optica. Mult Scler 2015. [Epub ahead of print] This study examined the pattern of expression of AQP-4 and regulators of complement activation (RCA) in the brain and peripheral organs. Unlike peripheral organs wherein cells coexpress AQP-4 and RCA, astrocytes lack RCA, which might explain the susceptibility of the CNS to the complement-mediated injury.
26. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221-2231.
27. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012;11:535-544.
28. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671.
29. Jiao Y, Fryer JP, Lennon VA, et al. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol 2014;71:48-54. This study emphasizes the superior sensitivity of recombinant antigen-based assays for NMO-IgG detection in patients with recurrent LETM.
30. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-569.
31. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-2200.
32. Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68:1412-1420.
33. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the longterm course of neuromyelitis optica. Brain 2008;131:3072-3080.
34. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76:1310-1315.
35. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82:474-481. This study provides insights into NMO-IgG seronegative NMO through identifying anti-MOG antibodies in a subset of patients. It not only detected overlapping characteristics but also some distinguishing group features of NMO-IgG seropositive NMO and anti-MOG seropositive NMO, suggesting that they could represent distinct disorders.
36. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-1277.
37. Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2014;1:e40. This study demonstrates association of anti-MOG antibody with bilateral and recurrent optic neuritis and suggests that the antibody may be a useful clinical biomarker.
38. Höftberger R, Sepulveda M, Armangue T, et al. Antibodies toMOGand AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2014;21:866-874. This study highlights better outcomes in anti-MOG patients with NMO, LETM and optic neuritis than in those with NMO-IgG.
39. Mayer MC, Breithaupt C, Reindl M, et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 2013;191:3594-3604.
40. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012;1:180-187.
41. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;326:581-588.
42. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013;28:145-284.
43. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878-886.
44. Bonnan M, Valentino R, Olindo S, et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009;15:487-492.
45. Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 2012;130:858-862.
46. Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol 2014;164:342-351.. This article reviews the possible mechanisms of action of plasma exchange.
47. Kim SH, Kim W, Huh SY, et al. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating antiaquaporin-4 antibody levels. J Clin Neurol 2013;9:36-42.
48. Kiprov DD, Golden P, Rohe R, et al. Adverse reactions associated with mobile therapeutic apheresis: analysis of 17, 940 procedures. J Clin Apher 2001;16:130-133.
49. Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014;20:501-504. This study indicates that adjunctive IVIg may have a role in treating acute NMO relapses.
50. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007;2:9-18.
51. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219-1220.
52. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011;77:659-666.
53. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 2014;20:1533-1540. This study shows that AZA is modestly effective treatment for NMO, but its tolerability is relatively poor.
54. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014;71:324-330. This retrospective analysis of relapse rate in 90 patients with NMO and NMOSD treated with RTX, AZA and MMF indicated that AZA exhibits efficacy inferior to RTX.
55. Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015;351:31-35. This retrospective chart review of 70 NMO and NMOSD patients on RTX, AZA, MMF and CYC suggested superior efficacy and comparable tolerability of RTX to other immunosuppressive agents.
56. Jones TS, Yang W, Evans WE, Relling MV. Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin Pharmacol Ther 2007;81:729-734.
57. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008;168:378-381.
58. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-1125.
59. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66:1128-1133.
60. Vodopivec I, Miloslavsky EM, Kotton CN, Cho TA. A neurologist's guide to safe use of immunomodulatory therapies. Semin Neurol 2014;34:467-478. This review provides guidelines for well tolerated and effective use of immunomodulatory therapies in patients with neuroimmunological conditions.
61. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-1272.
62. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-1448.
63. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-1164.
64. Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 2013;84:511-516.
65. Kim SH, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011;68:473-479.
66. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004;63:S28-S32.
67. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010;67:1131-1136.
68. Yaguchi H, Sakushima K, Takahashi I, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med 2013;52:969-972.
69. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013;84:918-921.
70. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007;13:968-974.
71. Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroidassociated adverse events: a systematic literature review. Clin Ther 2011;33:1413-1432.
72. Kageyama T, Komori M, Miyamoto K, et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 2013;260:627-634.
73. Khatri BO, Kramer J, Dukic M, et al. Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apher 2012;27:183-192.
74. Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol 2010;12:244-255.
75. Absoud M, Lim MJ, Appleton R, et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry 2015;86:470-472. This retrospective study of 22 children with NMO describes high risk of visual impairment and physical disability, similarly to adult NMO.
76. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008;71:93-100.
77. Longoni G, Banwell B, Filippi M, Yeh EA. Rituximab as a first-line preventive treatment in pediatric NMOSDs: preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm 2014;1:e46. This study in five children with NMOSD demonstrated that RTX stabilized or improved neurologic disability, reduced relapse rate and was well tolerated.
78. Bourre B, Marignier R, Zéphir H, et al. Neuromyelitis optica and pregnancy. Neurology 2012;78:875-879.
79. Fragoso YD, Adoni T, Bichuetti DB, et al. Neuromyelitis optica and pregnancy. J Neurol 2013;260:2614-2619.
80. Ringelstein M, Harmel J, Distelmaier F, et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler 2013;19:1544-1547.
81. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13:256-259.
82. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007;252:57-61.
83. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFN (-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010;75:1423-1427.
84. Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010;67:1016-1017.
85. Jacob A, Hutchinson M, Elsone L, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012;79:1065-1066.
86. Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012;18:108-112.
87. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-245.
88. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18:113-115.
89. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013;12:554-562.
90. Ayzenberg I, Kleiter I, Schröder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013;70:394-397.
91. Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 2014;82:1302-1306. This study in seven NMO and NMOSD patients showed that tocilizumab reduced relapse rate and was well tolerated.
92. Tradtrantip L, Zhang H, Saadoun S, et al. Antiaquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71:314-322.